SOAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Monotherapy in R/R PTCL achieved CBR of 53% in the cohort with proven activating JAK or STAT mutations; a CBR of 45% was achieved in the cohort with ≥30% pSTAT3 expression identified via immunohistochemistry